Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Key Points

Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease.

Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.

Full PDF

bloodjournal.org/content/bl...

2 Replies

oldestnewest
  • Photo so clear. Great.

    Not so sure about Idealisib.

    Sue

  • Excellent! I am on Zydelig and need to know what to look for

    Thanks